MGD009/MGA012 Combination in Relapsed/Refractory Cancer

NCT03406949 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

BIOLOGICAL: obrindatamab
BIOLOGICAL: retifanlimab

Sponsor

MacroGenics